Clinical trial
Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual…
NCT00153075 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00153075 |
|---|---|
| Title | Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD) |
| Official title | A Randomised Open Label, Six Way, Cross-over Scintigraphic Evaluation of the Effect of Inspiratory Flow Rate on Lung and Oropharyngeal Deposition With the Respimat Inhaler vs. a Metered Dose Inhaler (HFA-MDI) Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD). |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Pulmonary Disease, Chronic Obstructive, Asthma |
| Intervention type | Device |
| Interventions | Berodual Respimat, Berodual HFA-MDI |
| Enrollment | 19 |
| Start date | Sep 26, 2005 |
| Primary completion | Dec 7, 2005 |
| Completion | Dec 7, 2005 |
| First posted | Sep 12, 2005 |
| Last update posted | Nov 29, 2023 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: